Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
6 Results for "
Farletuzumab
" in MedChemExpress (MCE) Product Catalog:
Products (6)
6 Results for "Farletuzumab" in MCE Product Catalog:
Cat. No.: HY-P99153
CAS No.: 896723-44-7
Synonyms: MORAb-003
Target:
Research Areas:
Cat. No.: HY-P99612
CAS No.: 2407465-18-1
Synonyms: MORAb-202
Target:
Research Areas:
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
Cat. No.: HY-185773
Research Areas:
Farletuzumab-LNK4-S (DAR8) is an antibody-drug conjugate (ADC) with a drug-to-antibody ratio of 8. Farletuzumab-LNK4-S (DAR8) is conjugated from the anti-FRα antibody Farletuzumab (HY-P99153) and LNK4-S (HY-170400). Farletuzumab-LNK4-S (DAR8) can be used in cancer-related research .
Cat. No.: HY-185773A
Research Areas:
Farletuzumab-LNK4-S (DAR4) is an antibody-drug conjugate (ADC) with a drug-to-antibody ratio of 4. Farletuzumab-LNK4-S (DAR4) is prepared by conjugating the anti-FRα antibody Farletuzumab (HY-P99153) with LNK4-S (HY-170400). Farletuzumab-LNK4-S (DAR4) can be used in cancer-related research .
Cat. No.: HY-185774A
Target:
Research Areas:
ADC Control Human IgG1 (D356E/L358M)-LNK4 (DAR4) is a control antibody-drug conjugate (ADC) with a drug-to-antibody ratio (DAR) of 4, formed by the conjugation of Human IgG1 (D356E/L358M) kappa, Isotype Control (HY-P990100) and LNK4-S (HY-170400). ADC Control Human IgG1 (D356E/L358M)-LNK4 (DAR4) serves as the isotype control for Farletuzumab-LNK4-S (DAR4) (HY-185773A) .
Cat. No.: HY-185774
Target:
Research Areas:
ADC Control Human IgG1 (D356E/L358M)-LNK4 (DAR8) is a control ADC with a drug-to-antibody ratio (DAR) of 8, consisting of Human IgG1 (D356E/L358M) kappa, Isotype Control (HY-P990100), which does not specifically bind to FRα, and LNK4-S (HY-170400). ADC Control Human IgG1 (D356E/L358M)-LNK4 (DAR8) serves as the isotype control for Farletuzumab-LNK4-S (DAR8) (HY-185773) .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
